State Street
DSGN icon

State Street’s Design Therapeutics DSGN Stock Holding History

State Street’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Buy
736,221
+76,646
+12% +$956K ﹤0.01% 2674
2026
Q1 		$7.02M Buy
659,575
+11,939
+2% +$121K ﹤0.01% 2795
2025
Q4 		$6.07M Buy
647,636
+13,239
+2% +$104K ﹤0.01% 2899
2025
Q3 		$4.78M Sell
634,397
-84,815
-12% -$425K ﹤0.01% 3008
2025
Q2 		$2.42M Buy
719,212
+5,138
+0.7% +$19.2K ﹤0.01% 3243
2025
Q1 		$2.76M Sell
714,074
-9,245
-1% -$44.1K ﹤0.01% 3126
2024
Q4 		$4.46M Buy
723,319
+32,493
+5% +$188K ﹤0.01% 3023
2024
Q3 		$3.72M Sell
690,826
-4,597
-0.7% -$21.6K ﹤0.01% 3095
2024
Q2 		$2.33M Sell
695,423
-3,563
-0.5% -$13.9K ﹤0.01% 3262
2024
Q1 		$2.82M Buy
698,986
+3,762
+0.5% +$10K ﹤0.01% 3166
2023
Q4 		$1.84M Buy
695,224
+2,501
+0.4% +$5.73K ﹤0.01% 3337
2023
Q3 		$1.63M Buy
692,723
+106,688
+18% +$498K ﹤0.01% 3405
2023
Q2 		$3.69M Sell
586,035
-125,493
-18% -$768K ﹤0.01% 3148
2023
Q1 		$4.11M Sell
711,528
-2,325,932
-77% -$17.4M ﹤0.01% 3066
2022
Q4 		$31.2M Buy
3,037,460
+2,127,991
+234% +$28.8M ﹤0.01% 1936
2022
Q3 		$15.2M Buy
909,469
+459,688
+102% +$9.15M ﹤0.01% 2428
2022
Q2 		$6.3M Buy
449,781
+46,240
+11% +$625K ﹤0.01% 2980
2022
Q1 		$6.52M Buy
403,541
+61,280
+18% +$939K ﹤0.01% 3044
2021
Q4 		$7.33M Buy
342,261
+130,653
+62% +$2.24M ﹤0.01% 3062
2021
Q3 		$3.11M Buy
211,608
+23,519
+13% +$391K ﹤0.01% 3484
2021
Q2 		$3.74M Buy
+188,089
New +$4.75M ﹤0.01% 3375

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's DSGN Position: Q2 2026 in Review

State Street increased its Design Therapeutics (DSGN) stake by 12% in Q2 2026, buying an estimated $956K and bringing the position to 736,221 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2674.

State Street first reported a position in DSGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $31.2M in Q4 2022. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • State Street held 736,221 shares of Design Therapeutics worth $10.7M as of Q2 2026.
  • State Street bought 76,646 Design Therapeutics shares in Q2 2026, an estimated $956K.
  • Design Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2674 holding.
  • State Street first reported a position in Design Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • State Street's Design Therapeutics position peaked at $31.2M in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.